Abstract
Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography (SPECT) were prospectively investigated in 100 patients with major cerebral artery, atherosclerotic, and steno-occlusive diseases. All patients underwent two SPECT studies (with and without acetazolamide challenge) at an interval of 2 or 3 days, received a questionnaire immediately after each SPECT study, and returned the answered questionnaire within 7 days after the study. None of the 100 patients studied experienced any symptoms during the SPECT study without acetazolamide challenge. Sixty-three patients (63%) developed symptoms during the SPECT study with acetazolamide challenge, such as headache, nausea, dizziness, tinnitus, numbness of the extremities, motor weakness of the extremities, and general malaise 1-3 hours (mean 1.6 hours) after administration of acetazolamide, and these symptoms lasted for 0.5-72 hours (mean 7.9 hours). Multivariate statistical analysis revealed that younger age (95% confidence interval [CI] 0.896-0.980, p=0.0047) and female sex (95% CI 1.178-16.129, p=0.0274) were significantly associated with development of symptoms with acetazolamide challenge. The incidences of the development of symptoms with acetazolamide challenge were 91% (21/23) and 41% (12/29) in subgroups of women <70 years and men {>=}70 years, respectively. Patients should be informed of such adverse
More>>
Saito, Hideo;
Ogasawara, Kuniaki;
Suzuki, Taro;
Kuroda, Hiroki;
Kobayashi, Masakazu;
Yoshida, Kenji;
Kubo, Yoshitaka;
Ogawa, Akira
[1]
- Iwate Medical Univ., School of Medicine, Morioka, Iwate (Japan)
Citation Formats
Saito, Hideo, Ogasawara, Kuniaki, Suzuki, Taro, Kuroda, Hiroki, Kobayashi, Masakazu, Yoshida, Kenji, Kubo, Yoshitaka, and Ogawa, Akira.
Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography in patients with major cerebral artery steno-occlusive diseases.
Japan: N. p.,
2011.
Web.
doi:10.2176/nmc.51.479.
Saito, Hideo, Ogasawara, Kuniaki, Suzuki, Taro, Kuroda, Hiroki, Kobayashi, Masakazu, Yoshida, Kenji, Kubo, Yoshitaka, & Ogawa, Akira.
Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography in patients with major cerebral artery steno-occlusive diseases.
Japan.
https://doi.org/10.2176/nmc.51.479
Saito, Hideo, Ogasawara, Kuniaki, Suzuki, Taro, Kuroda, Hiroki, Kobayashi, Masakazu, Yoshida, Kenji, Kubo, Yoshitaka, and Ogawa, Akira.
2011.
"Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography in patients with major cerebral artery steno-occlusive diseases."
Japan.
https://doi.org/10.2176/nmc.51.479.
@misc{etde_21517948,
title = {Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography in patients with major cerebral artery steno-occlusive diseases}
author = {Saito, Hideo, Ogasawara, Kuniaki, Suzuki, Taro, Kuroda, Hiroki, Kobayashi, Masakazu, Yoshida, Kenji, Kubo, Yoshitaka, and Ogawa, Akira}
abstractNote = {Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography (SPECT) were prospectively investigated in 100 patients with major cerebral artery, atherosclerotic, and steno-occlusive diseases. All patients underwent two SPECT studies (with and without acetazolamide challenge) at an interval of 2 or 3 days, received a questionnaire immediately after each SPECT study, and returned the answered questionnaire within 7 days after the study. None of the 100 patients studied experienced any symptoms during the SPECT study without acetazolamide challenge. Sixty-three patients (63%) developed symptoms during the SPECT study with acetazolamide challenge, such as headache, nausea, dizziness, tinnitus, numbness of the extremities, motor weakness of the extremities, and general malaise 1-3 hours (mean 1.6 hours) after administration of acetazolamide, and these symptoms lasted for 0.5-72 hours (mean 7.9 hours). Multivariate statistical analysis revealed that younger age (95% confidence interval [CI] 0.896-0.980, p=0.0047) and female sex (95% CI 1.178-16.129, p=0.0274) were significantly associated with development of symptoms with acetazolamide challenge. The incidences of the development of symptoms with acetazolamide challenge were 91% (21/23) and 41% (12/29) in subgroups of women <70 years and men {>=}70 years, respectively. Patients should be informed of such adverse effects of intravenous acetazolamide administration prior to the acetazolamide challenge test for evaluation of cerebrovascular reactivity. (author)}
doi = {10.2176/nmc.51.479}
journal = []
issue = {7}
volume = {51}
place = {Japan}
year = {2011}
month = {Jul}
}
title = {Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography in patients with major cerebral artery steno-occlusive diseases}
author = {Saito, Hideo, Ogasawara, Kuniaki, Suzuki, Taro, Kuroda, Hiroki, Kobayashi, Masakazu, Yoshida, Kenji, Kubo, Yoshitaka, and Ogawa, Akira}
abstractNote = {Adverse effects of intravenous acetazolamide administration for evaluation of cerebrovascular reactivity using brain perfusion single-photon emission computed tomography (SPECT) were prospectively investigated in 100 patients with major cerebral artery, atherosclerotic, and steno-occlusive diseases. All patients underwent two SPECT studies (with and without acetazolamide challenge) at an interval of 2 or 3 days, received a questionnaire immediately after each SPECT study, and returned the answered questionnaire within 7 days after the study. None of the 100 patients studied experienced any symptoms during the SPECT study without acetazolamide challenge. Sixty-three patients (63%) developed symptoms during the SPECT study with acetazolamide challenge, such as headache, nausea, dizziness, tinnitus, numbness of the extremities, motor weakness of the extremities, and general malaise 1-3 hours (mean 1.6 hours) after administration of acetazolamide, and these symptoms lasted for 0.5-72 hours (mean 7.9 hours). Multivariate statistical analysis revealed that younger age (95% confidence interval [CI] 0.896-0.980, p=0.0047) and female sex (95% CI 1.178-16.129, p=0.0274) were significantly associated with development of symptoms with acetazolamide challenge. The incidences of the development of symptoms with acetazolamide challenge were 91% (21/23) and 41% (12/29) in subgroups of women <70 years and men {>=}70 years, respectively. Patients should be informed of such adverse effects of intravenous acetazolamide administration prior to the acetazolamide challenge test for evaluation of cerebrovascular reactivity. (author)}
doi = {10.2176/nmc.51.479}
journal = []
issue = {7}
volume = {51}
place = {Japan}
year = {2011}
month = {Jul}
}